rF1V vaccine

BIOLOGICAL3 trials

Sponsors

DynPort Vaccine Company LLC, A GDIT Company, Dynavax Technologies Corporation

Conditions

Healthy VolunteersPlaguePlague, PneumonicPneumonic PlaguePreventive TherapyVaccine-Preventable Diseases

Phase 1

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

CompletedNCT00097396

DynPort Vaccine Company LLC, A GDIT CompanyPneumonic Plague, Preventive Therapy

Start: 2004-11-30End: 2006-09-30Target: 40Updated: 2011-06-30

Phase 2

Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers

CompletedNCT00332956

DynPort Vaccine Company LLC, A GDIT CompanyHealthy Volunteers

Start: 2006-05-31End: 2008-10-31Updated: 2011-12-02

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

CompletedNCT05506969

Dynavax Technologies CorporationPlague, Plague, Pneumonic, Vaccine-Preventable Diseases

Start: 2022-08-09End: 2024-04-26Updated: 2025-07-29